CompoSecure Reports Record Full Year 2022 Financial Results and Issues 2023 Outlook
FY
Q4
Expects 2023 Net Sales Between
“Our fourth quarter performance capped off a remarkable year for
Full Year 2022 Financial Highlights (vs. FY 2021)
Net Sales :Net Sales increased 41% to$378.5 million compared to$267.9 million .- Gross Profit: Gross Profit increased 52% to
$219.6 million or 58% ofNet Sales , compared to$144.8 million or 54.1%. - Net Income/EPS: Net Income increased 58% to
$131.8 million compared to$83.4 million . Net Income per share attributable to class A common stockholders was$1.21 (Basic) and$1.13 (Diluted). - Adjusted Net Income/Adjusted EPS: Adjusted Net Income (a non-GAAP measure) was
$83.0 million . Adjusted EPS (a non-GAAP measure), which includes both class A and class B shares, was$1.10 (Basic) and$0.94 (Diluted) (see reconciliation of non-GAAP measures shown in table below). - Adjusted EBITDA: Adjusted EBITDA (a non-GAAP measure) increased 33% to
$136.2 million compared to$102.3 million . - Balance Sheet: As of
December 31, 2022 , the Company had$13.6 million of cash and cash equivalents and$363 million of total debt, which includes$233 million of term loan, and$130 million of exchangeable notes. - Shares Outstanding: As of
December 31, 2022 , the Company had approximately 76.7 million shares outstanding which includes approximately 16.4 million class A shares and approximately 60.3 million class B shares (for more information on shares outstanding, both Basic and Diluted, please refer to the Company’s 10-K and the accompanying earnings presentation).
Q4 2022 Financial Highlights (vs. Q4 2021)
Net Sales :Net Sales increased 25% to$93.8 million compared to$75.3 million , with the increase primarily driven by strong sales execution, growth from new and existing programs, and continued international demand.- Gross Profit: Gross Profit increased 28% to
$50.3 million or 53.6% ofNet Sales , compared to$39.3 million or 52.2%. The increase in Gross Profit and margin was primarily driven by improved operational efficiencies and volume. - Net Income/EPS: Net Income increased 12% to
$22.4 million compared to$20.0 million . Net Income per share attributable to class A common stockholders was$0.14 (Basic) and$0.14 (Diluted). - Adjusted Net Income/Adjusted EPS: Adjusted Net Income (a non-GAAP measure) was
$17.7 million . Adjusted EPS (a non-GAAP measure), which includes both class A and class B shares, was$0.23 (Basic) and$0.20 (Diluted) (see reconciliation of non-GAAP measures shown in table below). - Adjusted EBITDA: Adjusted EBITDA (a non-GAAP measure) increased 44% to
$30.6 million compared to$21.2 million , with the increase primarily driven byNet Sales growth, margin expansion, as well as managing investments related to Arculus.
Recent Operational Highlights
- Enhanced security for cardholders:
- Secure Authentication – received approval from
Visa and Mastercard to add secure authentication to payment cards using FIDO2 technology and working on pilots with several customers. - Biometric Card – includes a fingerprint sensor on a metal payment card delivering enhanced security at the point of a transaction.
- Dynamic CVV – converts the 3-digit CVV code from a static number printed on the back of the metal card to a tiny e-ink screen that refreshes the CVV periodically.
- Secure Authentication – received approval from
- Launched innovative payment card designs:
- LED Card – makes the issuing bank logo light up with LEDs when a contactless transaction is initiated at the point of sale.
- Lux Glass™ Card – CompoSecure is the first to manufacture a transparent payment card made of
Corning ® Gorilla® Glass with a metal bezel. - Echo Mirror™ Card – a buffed stainless-steel payment card with a mirror-like finish, and a protective coating.
- Enhancing Arculus cold storage wallet B2B and B2C functionality to include support for more than 10K coins, superior security for card to mobile device communication, and expanded wallet connect and Defi access.
- Successfully completed and received independent SOC 2 Type 2 audit attestation.
2023 Financial Outlook
Conference Call
The Company will host a conference call and live audio webcast today at
Date:
Time:
Dial-in registration link: here
Live webcast registration link: here
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
A live webcast and replay of the conference call will be available on the investor relations section of the Company’s website at https://ir.composecure.com/news-events/events.
About
Founded in 2000,
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management. Although the Company believes that its plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning the Company’s possible or assumed future actions, business strategies, events, or results of operations, are forward-looking statements. In some instances, these statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements which speak only as of the date hereof. You should understand that the following important factors, among others, could affect the Company’s future results and could cause those results or other outcomes to differ materially from those expressed or implied in the Company’s forward-looking statements: the outcome of any legal proceedings that may be instituted against the Company or others; the impacts of the ongoing COVID-19 pandemic; the ability of the Company to grow and manage growth profitably, maintain relationships with customers, compete within its industry and retain its key employees; the possibility that the Company may be adversely impacted by other economic conditions (including the rapidly evolving conflict between Russian and the Ukraine), business, and/or competitive factors; future exchange and interest rates; and other risks and uncertainties included under “Risk Factors” in other Company filings that have been made or will be made with the Securities and Exchange Commission. The Company undertakes no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in
Corporate Contact
Head of Communications,
(908) 898-8887
apiniella@composecure.com
Investor Relations Contact
Elevate IR
(720) 330-2829
ir@composecure.com
Condensed Consolidated Balance Sheet Data | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
ASSETS | |||||||
Cash and cash equivalents | $ | 13,642 | $ | 21,944 | |||
Accounts Receivable, net | 37,272 | 27,925 | |||||
Inventories | 42,374 | 25,806 | |||||
Prepaid expenses and other current assets | 3,824 | 2,596 | |||||
Property and equipment, net | 22,655 | 22,177 | |||||
Right of use asset, net | 8,932 | 5,246 | |||||
Deferred tax asset | 25,569 | 25,650 | |||||
Derivative asset - interest rate swap | 8,651 | - | |||||
Deposits and other assets | 24 | 10 | |||||
TOTAL ASSETS | $ | 162,943 | $ | 131,354 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current portion of long-term debt | $ | 14,372 | 12,500 | ||||
Current portion of lease liabilities | 1,846 | 1,119 | |||||
Accounts payable | 7,127 | 7,058 | |||||
Accrued expenses | 10,154 | 10,131 | |||||
Deferred issuance costs | - | 23,107 | |||||
Commission payable | 3,317 | 3,089 | |||||
Bonus payable | 8,177 | 3,512 | |||||
Long-term debt, net of deferred finance costs | 216,276 | 233,132 | |||||
Convertible notes, net of debt discount | 127,348 | 126,897 | |||||
Derivative liability - convertible notes | 285 | 552 | |||||
Warrant liability | 16,341 | 35,271 | |||||
Line of credit | - | 15,000 | |||||
Earnout liability | 15,090 | 38,427 | |||||
Lease liabilities | 7,766 | 4,709 | |||||
Tax receivable agreement liability | 26,842 | 24,500 | |||||
Total stockholders' (deficit) | (291,998 | ) | (407,650 | ) | |||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 162,943 | $ | 131,354 | |||
Consolidated Statements of Operations | ||||||||||||||
(in thousands, except per share amounts) | ||||||||||||||
(unaudited) | ||||||||||||||
Three Months Ended |
Years Ended |
|||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||
Net sales | $ | 93,790 | $ | 75,300 | $ | 378,476 | $ | 267,948 | ||||||
Operating expenses: | ||||||||||||||
Cost of sales | 43,514 | 36,025 | 158,832 | 123,099 | ||||||||||
Selling, General and administrative | 25,425 | 30,076 | 104,749 | 63,424 | ||||||||||
Total operating expenses | 68,939 | 66,101 | 263,581 | 186,523 | ||||||||||
Income from operations | 24,851 | 9,199 | 114,895 | 81,425 | ||||||||||
Total other income (expense), net | (1,872 | ) | 9,962 | 21,280 | 1,132 | |||||||||
Income before income taxes | 22,979 | 19,161 | 136,175 | 82,557 | ||||||||||
Income tax provision | (622 | ) | 857 | (4,360 | ) | 857 | ||||||||
Net income | 22,357 | 20,018 | 131,815 | 83,414 | ||||||||||
Net income attributable to non-controlling interests | 20,113 | 16,864 | 113,158 | 80,260 | ||||||||||
Net income attributable to |
$ | 2,243 | $ | 3,154 | $ | 18,657 | $ | 3,154 | ||||||
Net income per share attributable to Class A common stockholders -basic | $ | 0.14 | $ | 0.21 | $ | 1.21 | $ | 0.21 | ||||||
Net income per share attributable to Class A common stockholders - diluted | $ | 0.14 | $ | 0.12 | $ | 1.13 | $ | 0.12 | ||||||
Weighted average shared used to compute net income per share attributable to Class A common stockholders - basic | 16,059 | 14,930 | 15,372 | 14,930 | ||||||||||
Weighted average shared used to compute net income per share attributable to Class A common stockholders - diluted | 16,059 | 94,570 | 32,555 | 94,570 |
Consolidated Statements of Cash Flows | |||||||
(in thousands) | |||||||
(unaudited) | |||||||
Year Ended |
|||||||
2022 | 2021 | ||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||
Net income | $ | 131,815 | $ | 83,414 | |||
Adjustments to reconcile net income to net cash provided by operating activities | |||||||
Depreciation | 8,575 | 10,428 | |||||
Equity-based compensation expense | 11,465 | 6,113 | |||||
Amortization of deferred finance costs | 2,345 | 1,654 | |||||
Inventory Reserve | 1,668 | 600 | |||||
Change in fair value of earnout consideration liability | (23,337 | ) | (9,575 | ) | |||
Revaluation of warrant liability | (18,930 | ) | (3,485 | ) | |||
Change in fair value of derivative liability | (266 | ) | - | ||||
Deferred tax expense (benefit) | 3,193 | (857 | ) | ||||
Changes in assets and liabilities | |||||||
Accounts receivable | (9,347 | ) | (19,133 | ) | |||
Inventories | (18,237 | ) | 3,792 | ||||
Prepaid expenses and other assets | (1,228 | ) | (1,519 | ) | |||
Accounts payable | 68 | 4,637 | |||||
Deposits | (14 | ) | - | ||||
Accrued expenses | 23 | 1,665 | |||||
Other liabilities | 4,990 | 46 | |||||
Net cash provided by operating activities | 92,783 | 77,780 | |||||
CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||
Acquisition of property and equipment | (9,053 | ) | (4,746 | ) | |||
Net cash used in investing activities | (9,053 | ) | (4,746 | ) | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||
Business combination and PIPE financing | - | 60,826 | |||||
Proceeds from convertible notes | - | 127,400 | |||||
Proceeds from employee stock purchase plan and exercise of equity awards | 82 | - | |||||
Proceeds from Term Loan | - | 250,000 | |||||
Payment of line of credit | (15,000 | ) | (5,000 | ) | |||
Deferred finance costs related to debt origination | - | (1,860 | ) | ||||
Payment of term loan | (16,878 | ) | (240,000 | ) | |||
Payment of Tax receivable agreement liability | (110 | ) | - | ||||
Distributions pursuant to the business combination | - | (218,300 | ) | ||||
Distributions to Holdings's members | (36,293 | ) | (22,334 | ) | |||
Payment of issuance cost related to business combination | (23,833 | ) | (15,244 | ) | |||
Net cash used in financing activities | (92,032 | ) | (64,512 | ) | |||
Net decrease in cash and cash equivalents | (8,302 | ) | 8,522 | ||||
Cash and cash equivalents, beginning of period | 21,944 | 13,422 | |||||
Cash and cash equivalents, end of period | $ | 13,642 | $ | 21,944 | |||
Supplementary disclosure of cash flow information | |||||||
Cash paid for interest expense | $ | 21,379 | $ | 10,101 | |||
Supplemental disclosure of non-cash financing activity: | |||||||
Derivative asset - interest rate swap | $ | 8,651 | $ | - | |||
Issuance costs payable | $ | - | $ | 23,107 | |||
Non-GAAP Adjusted EBITDA Reconciliation | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Years Ended |
|||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Net income | $ | 22,357 | $ | 20,018 | $ | 131,815 | $ | 83,414 | ||||||||
Add: | ||||||||||||||||
Depreciation | 1,998 | 2,615 | 8,575 | 10,428 | ||||||||||||
Interest expense, net | 6,182 | 3,098 | 22,544 | 11,928 | ||||||||||||
Taxes | 622 | (857 | ) | 4,360 | (857 | ) | ||||||||||
EBITDA | $ | 31,159 | $ | 24,874 | $ | 167,294 | $ | 104,913 | ||||||||
Special management bonus expense | - | 4,384 | - | 4,384 | ||||||||||||
Equity compensation expense | 3,730 | 4,989 | 11,465 | 6,113 | ||||||||||||
Mark to market adjustments (1) | (4,310 | ) | (13,060 | ) | (42,533 | ) | (13,060 | ) | ||||||||
Adjusted EBITDA | $ | 30,579 | $ | 21,187 | $ | 136,226 | $ | 102,350 | ||||||||
(1) Includes the changes in fair value of warrant liability, derivative liabilities and earnout consideration liability. | ||||||||||||||||
Non-GAAP Adjusted EPS Reconciliation | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
Three Months Ended |
Year Ended |
|||||||||||||||
2022 | 2022 | |||||||||||||||
(in thousands) except per share amounts | ||||||||||||||||
Basic | Diluted | Basic | Diluted | |||||||||||||
Net income | $ | 22,357 | $ | 22,357 | $ | 131,815 | $ | 131,815 | ||||||||
Add: provision for income taxes | 622 | 622 | 4,360 | 4,360 | ||||||||||||
Income before Income taxes | 22,979 | 22,979 | 136,175 | 136,175 | ||||||||||||
Income tax expense (1) | (4,784 | ) | (4,784 | ) | (22,423 | ) | (22,423 | ) | ||||||||
Adjusted net income | 18,195 | 18,195 | 113,752 | 113,752 | ||||||||||||
Less: mark-to-market adjustments (2) | (4,227 | ) | (4,227 | ) | (42,267 | ) | (42,267 | ) | ||||||||
Add: stock-based compensation | 3,730 | 3,730 | 11,465 | 11,465 | ||||||||||||
Adjusted net income | $ | 17,698 | $ | 17,698 | $ | 82,950 | $ | 82,950 | ||||||||
Common shares outstanding used in computing earnings per share, basic: | ||||||||||||||||
Class A and Class B common shares (3) | 76,384 | 76,384 | 75,697 | 75,697 | ||||||||||||
Common shares outstanding used in computing earnings per share, diluted: | ||||||||||||||||
Warrants (Public and Private) (4) | - | 8,094 | - | 8,094 | ||||||||||||
Options and restricted common shares | - | 3,859 | - | 4,183 | ||||||||||||
Total Shares outstanding used in computing adjusted earnings per share | 76,384 | 88,337 | 75,697 | 87,974 | ||||||||||||
Adjusted earnings per share (5) | $ | 0.23 | $ | 0.20 | $ | 1.10 | $ | 0.94 | ||||||||
1) Calculated using the Company's blended tax rate. | ||||||||||||||||
2) Includes the changes in fair value of warrant liability and earnout consideration liability. | ||||||||||||||||
3) Assumes both Class A shares and Class B shares participate in earnings and are outstanding at the end of the period. | ||||||||||||||||
4) Assumes treasury stock method, valuation at assumed fair market value of |
||||||||||||||||
5) The Company did not include the effect of Exchangeable Notes to its total shares outstanding used in diluted adjusted net income per share. | ||||||||||||||||
Source: CompoSecure, Inc.